[Validity, clinical utility and safety of the next-generation sequencing (NGS) genomic platform FoundationOne® in non-small cell lung cancer and other solid tumors]
Ascensio del Barrio C, Carpintero EG, Rodríguez MC
Record ID 32018001726
Spanish
Original Title:
Validez, utilidad clínica y seguridad de la nueva plataforma genómica de secuenciación de próxima generación (NGS) FoundationOne® en el cáncer de pulmón no microcítico y otros tipos de tumores sólidos
Authors' objectives:
The main objective of this report is to assess the diagnostic validity, clinical utility and safety of F1 or F1CDx as NGS platforms for the diagnosis of genomic alterations associated with solid tumors and their therapeutic recommendation
Authors' results and conclusions:
F1/F1CDx has the diagnostic capacity to identify GAs and therapeutic targets in patients with cancer, but due to the low quality of the included studies, it is necessary to carry out new studies to confirm the diagnostic results and the clinical usefulness of the test, as well as to evaluate both the potential toxicity associated with the therapies recommended by the test and the toxicity avoided by ruling out the use of ineffective drugs
Details
Project Status:
Completed
Year Published:
2019
URL for published report:
https://redets.sanidad.gob.es/productos/buscarProductos.do?metodo=detalle&id=944
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
Country:
Spain
MeSH Terms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Neoplasms
- Biomarkers, Tumor
- Genomics
- Genetic Testing
Keywords
- FoundationOne; Diagnostic validity; Clinic Utility
Contact
Organisation Name:
Agencia de Evaluacion de Tecnologias Sanitarias
Contact Address:
Instituto de Salud "Carlos III", Calle Sinesio Delgado 6, Pabellon 4, 28029 Madrid, Spain. Tel: +34 9 1 822 2005; Fax: +34 9 1 387 7841;
Contact Name:
Luis M. Sánchez Gómez
Contact Email:
luism.sanchez@isciii.es
Copyright:
Agencia de Evaluacion
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.